Benzinga··Vandana SinghGoodRx Surges on Wegovy HD Expansion, Tapping $399/Month Self-Pay Obesity Market
GoodRx shares rose 2.69% as the platform expands access to Novo Nordisk's Wegovy HD at $399/month, capitalizing on the surging self-pay GLP-1 obesity treatment market.
LLYNVOGDRXobesity treatmentGLP-1 treatments